{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:07:04Z","timestamp":1761581224936},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1097\/rlu.0000000000000562","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T10:52:25Z","timestamp":1408531945000},"page":"951-959","source":"Crossref","is-referenced-by-count":10,"title":["Whole-Body 18F-Fluorocholine (FCH) PET\/CT and MRI of the Spine for Monitoring Patients With Castration-Resistant Prostate Cancer Metastatic to Bone"],"prefix":"10.1097","volume":"39","author":[{"given":"Sona","family":"Balogova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph Ben","family":"Zakoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Tassart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adoracion","family":"Esteso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaldoun","family":"Kerrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Huchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-France","family":"Carette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Lotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-No\u00ebl","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210204","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"R2-3-20210204","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/10898600-000000000-00000","article-title":"Castration-resistant prostate cancer: current and emerging treatment strategies.","volume":"70","author":"Di Lorenzo","year":"2010","journal-title":"Drugs"},{"key":"R3-3-20210204","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","article-title":"Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.","volume":"31","author":"Halabi","year":"2013","journal-title":"J Clin Oncol"},{"key":"R4-3-20210204","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R5-3-20210204","first-page":"287","article-title":"The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-Fluoride PET, and 18F-Fluoride PETCT.","volume":"47","author":"Even-Sapir","year":"2006","journal-title":"J Nucl Med"},{"key":"R6-3-20210204","first-page":"448","article-title":"Fluorocholine(18F) and sodium fluoride(18F) PETCT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.","volume":"55","author":"Langsteger","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R7-3-20210204","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2214\/ajr.142.4.773","article-title":"The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.","volume":"142","author":"Pollen","year":"1984","journal-title":"AJR Am J Roentgenol"},{"key":"R8-3-20210204","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.","volume":"17","author":"Ryan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R9-3-20210204","first-page":"332","article-title":"Etidronate sodium therapy. A cause of poor skeletal radiopharmaceutical uptake.","volume":"21","author":"De Meo","year":"1991","journal-title":"Semin Nucl Med"},{"key":"R10-3-20210204","first-page":"374","article-title":"Diagnosis of bone metastasis: recent comparative studies of imaging modalities.","volume":"55","author":"Talbot","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R11-3-20210204","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2191-219X-1-4","article-title":"18F -fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin).","volume":"1","author":"Cook","year":"2011","journal-title":"EJNMMI Res"},{"key":"R12-3-20210204","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2214\/AJR.05.0225","article-title":"Flare response in 18F-fluoride ion PET bone scanning.","volume":"186","author":"Wade","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"R13-3-20210204","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.clon.2009.11.007","article-title":"Frequency of screening magnetic resonance imaging to detect occult spinal cord compromise and to prevent neurological deficit in metastatic castration-resistant prostate cancer.","volume":"22","author":"Venkitaraman","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R14-3-20210204","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.1998.16.5.1835","article-title":"Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.","volume":"16","author":"Smith","year":"1998","journal-title":"J Clin Oncol"},{"key":"R15-3-20210204","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/91.3.244","article-title":"Posttherapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.","volume":"91","author":"Scher","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R16-3-20210204","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO.2002.10.022","article-title":"Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480.","volume":"20","author":"Small","year":"2002","journal-title":"J Clin Oncol"},{"key":"R17-3-20210204","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djj129","article-title":"Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.","volume":"98","author":"Petrylak","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"R18-3-20210204","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Analysis of prostate-specific antigen decline as a surrogate for overall survival in metastatic hormone-refractory prostate cancer (HRPC): A TAX327 analysis.","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"R19-3-20210204","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0022-5347(05)64906-3","article-title":"Comparison of 18Ffluorocholine and 18Ffluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.","volume":"168","author":"Price","year":"2002","journal-title":"J Urol"},{"key":"R20-3-20210204","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00259-010-1579-x","article-title":"18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging.","volume":"38","author":"McCarthy","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-3-20210204","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.rlu.0000082670.19100.83","article-title":"Diffusely increased F-18 FDG uptake in bone marrow in a patient with acute anemia and recent erythropoietin therapy.","volume":"28","author":"Plantade","year":"2003","journal-title":"Clin Nucl Med"},{"key":"R22-3-20210204","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/RLU.0b013e31827a2294","article-title":"Effect of erythropoietin on bone marrow uptake of F-18 fluorocholine in prostate cancer. Comparison with F-18 fluoride uptake.","volume":"38","author":"Balogova","year":"2013","journal-title":"Clin Nucl Med"},{"key":"R23-3-20210204","first-page":"413","article-title":"Consequence of pegfilgrastim treatment on fluorocholine (18F) uptake by bone marrow.","volume":"36","author":"Balogova","year":"2012","journal-title":"Med Nucl"},{"key":"R24-3-20210204","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/jmri.22542","article-title":"Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.","volume":"33","author":"Eiber","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"R25-3-20210204","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00330-010-1879-3","article-title":"Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa).","volume":"20","author":"Lecouvet","year":"2010","journal-title":"Eur Radiol"},{"key":"R26-3-20210204","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/jmri.22608","article-title":"Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis.","volume":"34","author":"Wu","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"R27-3-20210204","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1148\/radiol.2492080038","article-title":"Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PETCT for detection of bone metastases.","volume":"249","author":"Luboldt","year":"2008","journal-title":"Radiology"},{"key":"R28-3-20210204","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/pros.20280","article-title":"Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases.","volume":"65","author":"Tombal","year":"2005","journal-title":"Prostate"},{"key":"R29-3-20210204","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1148\/radiol.10092469","article-title":"Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion mapsinitial observations.","volume":"257","author":"Reischauer","year":"2010","journal-title":"Radiology"},{"key":"R30-3-20210204","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00330-011-2173-8","article-title":"Assessing response in bone metastases in prostate cancer with diffusion weighted MRI.","volume":"21","author":"Messiou","year":"2011","journal-title":"Eur Radiol"},{"key":"R31-3-20210204","first-page":"624","article-title":"Diffusion-weighted MR imaging: adjunct or alternative to T1-weighted MR imaging for prostate carcinoma bone metastases Radiology.","volume":"252","author":"Lecouvet","year":"2009","journal-title":""}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000000562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:09:44Z","timestamp":1620972584000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201411000-00003"}},"subtitle":["A Pilot Study"],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000000562","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}